Guillain-Barre Syndrome Market Trends, Growth, Forecast 2024-2032
Guillain-Barre Syndrome Market Trends, Growth, Forecast 2024-2032

Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Mar-2024
  • Pages: 118
  • Format: PDF
  • Report ID: PM4787
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

Global guillain-barre syndrome market size was valued at USD 613.92 million in 2023. The market is anticipated to grow from USD 644.24 million in 2024 to USD 960.58 million by 2032, exhibiting the CAGR of 5.1% during the forecast period.

Market Overview

The Guillain-Barre Syndrome (GBS) market is poised for growth, driven by the rising incidence of the condition, particularly in regions with high rates of infectious diseases. GBS is a rare neurological disorder characterized by muscle weakness, and its occurrence is often associated with preceding infections, such as respiratory or gastrointestinal illnesses. The increasing prevalence of infectious diseases in certain regions is contributing to the heightened incidence of GBS, consequently propelling market expansion.

Guillain-Barre Syndrome Market Size

To Understand More About this Research: Request a Free Sample Report

Moreover, advancements in diagnostic techniques are facilitating early and accurate diagnosis of GBS, enabling prompt initiation of treatment. This, coupled with growing research and development activities focused on novel treatments, is further fueling market growth. Immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and plasmapheresis, are emerging as key treatment modalities for GBS, driving demand for these therapies and positively impacting market dynamics.

In addition, the rising investment in healthcare infrastructure and the increasing awareness about neurological disorders are creating a conducive environment for market growth. These factors, along with ongoing efforts to improve treatment outcomes and patient care, are expected to sustain the upward trajectory of the Guillain-Barre Syndrome market over the forecast period.

Growth Drivers

Rising prevalence of Guillain-Barre syndrome cases

The rising prevalence of Guillain-Barre syndrome (GBS) cases is significantly increasing the demand for products and services in the GBS market. GBS is a rare neurological disorder that affects the peripheral nervous system, leading to muscle weakness and, in severe cases, paralysis. With an increasing number of reported cases globally, there is a growing need for effective diagnostic tools, treatments, and supportive care services to address the disease burden.

Healthcare providers are increasingly seeking advanced diagnostic techniques to diagnose GBS and initiate timely interventions accurately. Additionally, the demand for immunomodulatory therapies such as intravenous immunoglobulin (IVIG) and plasmapheresis is rising as they are considered standard treatments for GBS. This growing demand for diagnostic tools and treatment options is propelling market growth and encouraging investments in research and development aimed at improving patient outcomes and quality of life.

Increase in the risk of having Guillain-Barre syndrome.

Guillain-Barre syndrome is becoming more prevalent among people with surgeries, infections, and vaccinations. The COVID-19 pandemic influenced the penetration of Guillain-Barre syndrome and contributed to the critical need for Guillain-Barre treatment facilities. For instance, a study published in the JAMA Neurology journal in 2024 showed a significant increase in the risk of having Guillain-Barre syndrome disease with the adenovirus COVID vaccination.

Furthermore, in July 2021, the US Food and Drug Administration announced the side effects of developing Guillain-Barre syndrome with the Johnson & Johnson vaccine, which is no longer available in the United States, according to the US Centres for Disease Control and Prevention in 2023.

Restraining Factors

Lower awareness about the treatment is likely to impede the guillain-barre syndrome market growth.

The market faces a significant challenge due to lower awareness about the available treatments, which is likely to impede the guillain-barre syndrome market growth. Despite advancements in diagnostic techniques and treatment modalities, there remains a lack of widespread knowledge about GBS among healthcare providers and the general population. This lower awareness leads to delays in diagnosis and initiation of appropriate treatment, thereby impacting patient outcomes.

Efforts to enhance awareness about GBS, its symptoms, and available treatment options are crucial for addressing this challenge. Educational initiatives targeting healthcare professionals, patients, and caregivers can play a pivotal role in improving early detection and access to treatment. Collaborative efforts between healthcare organizations, advocacy groups, and government agencies are needed to raise awareness about GBS, ultimately facilitating better management of the disease and supporting guillain-barre syndrome market growth.

Guillain-Barre Syndrome Market Share

Report Segmentation

The market is primarily segmented based on therapeutics, route of administration, distribution channel, and region.

By Therapeutic Area

By Route of Administration

By Distribution Channel

By Region

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others


  • Oral
  • Parental



  • Hospital Pharmacies
  • Retail Pharmacies
  • Others



  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Therapeutics Analysis

The Intravenous Immunoglobulin segment is expected to witness the highest guillain-barre syndrome market growth during the forecast period.

The intravenous immunoglobulin segment is projected to grow at a CAGR during the projected period, mainly driven by its capacity to lower the severity of the disease due to its potential to normalize the immune systems of people. It is cost-effective and limits the immune attack in the human nervous system, leading to a decrease in recovery duration. According to a 2023 comparative study published in Science Direct on intravenous immunoglobulin and plasma, the ease of use of intravenous immunoglobulin is likely to be the main factor driving its application in Guillain-Barre syndrome treatment procedures.

The plasma exchange segment led the industry market with a substantial guillain-barre syndrome market share in 2023, largely attributable to its ability to offer safety by taking or removing the harmful antibodies present in blood that cause nerve infection. Plasma exchange is currently gaining momentum with rising research on unraveling the side effects of intravenous immunoglobulin therapy.

By Route of Administration Analysis

Parental segment accounted for the largest guillain-barre syndrome market share in 2023

The parental segment accounted for the largest guillain-barre syndrome market share. This growth is highly influenced by the increased prescription of intravenous immunoglobulin therapy, as it involves the injection of antibodies to control inflammation through the parental route of administration, which involves subcutaneous, intravenous, and intramuscular. Its ability to transmit instant medication to the target area is driving its adoption in the marketplace.

By Distribution Channel Analysis

Hospital pharmacies segment held the significant guillain-barre syndrome market share in 2023

The hospital pharmacies segment garnered the largest guillain-barre syndrome market share due to the increasing number of people approaching hospitals for neurological disorders. Hospital pharmacies are showing interest in adopting significant healthcare medications with the rising prevalence of auto-immune diseases, including intravenous immunoglobulin and plasma therapeutics.

Guillain-Barre Syndrome Market Share

Regional Insights

North America region registered the largest guillain-barre syndrome market share in 2023

The North American region dominated the market. This segmentation is attributed to the presence of major players investing in research activities, primarily in the United States. For instance, Arialys Therapeutics, a biotechnology firm, raised USD 58 million in a seed financing round, aiming to develop therapeutics for autoimmune neuropsychiatric diseases.

Furthermore, government initiatives are likely to propel healthcare innovations in the region. For instance, the Rare Disease Cures Accelerator-Data and Analytics Platform will be unveiled in 2021 to promote the detection and innovation of rare diseases in partnership with the National Organization for Rare Disorders (NORD), the U.S. Food and Drug Administration (FDA), and the Critical Path Institute (C-Path).

The Asia Pacific will grow rapidly, owing to the growing number of companies dealing with the development of early detection kits for auto-immune diseases, which is anticipated to drive market expansion positively. For instance, in September 2023, NeoDx Biotech Labs, a Bangalore-based start-up, unveiled the IVD kit aiming to detect autoimmune disorders. The country's initiatives to promote self-sufficiency in their region are optimally boosting healthcare infrastructure growth. 

Guillain-Barre Syndrome Market Share

Key Market Players & Competitive Insights

The Guillain-Barre syndrome market is highly fragmented. The rising number of companies engaging in therapeutic formulations and growing expansion activities are likely to enhance the growth of the market in the assessment period. For instance, in 2022, NPO Microgen announced the launch of its new drug, BioGam, for the treatment of immunodeficiency.

Some of the major players operating in the global market include:

  • Annexon Inc.
  • Bayer AG
  • Biotest AG
  • Cellenkos Inc
  • China Biologic Products Holdings Inc
  • CSL Limited
  • Grifols S A
  • Kedrion Biopharma Inc
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited

Recent Developments in the Industry

  • In March 2022, during the American Academy of Neurology (AAN) 2022 conference, Annexon Biosciences unveiled preclinical data endorsing complement inhibitor initiatives aimed at treating Guillain-Barré syndrome and Huntington's disease.
  • In December 2020, Annexon, Inc. announced the initiation of patient dosing in a Phase 2/3 clinical trial evaluating the efficacy of ANX005, a full-length monoclonal antibody, for the treatment of Guillain-Barré Syndrome (GBS).

Report Coverage

The Guillain-Barre syndrome market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, therapeutics, route of administration, distribution channel, and their futuristic growth opportunities.

Guillain-Barre Syndrome Market Report Scope

Report Attributes


Market size value in 2024

USD 644.24 million

Revenue Forecast in 2032

USD 960.58 million


5.1% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

  • By Therapeutics
  • By Route of Administration
  • By Distribution Channel
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Guillain-Barre Syndrome Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel


Report customization as per your requirements with respect to countries, regions, and segmentation.


The Guillain-Barre Syndrome Market report covering key segments are therapeutics, route of administration, distribution channel, and region.

Guillain-Barre Syndrome Market Size Worth $960.58 Million By 2032

Guillain-Barre Syndrome Market exhibiting the CAGR of 5.1% during the forecast period.

North America is leading the global market

key driving factors in Guillain-Barre Syndrome Market are • Rising prevalence of Guillain-Barre syndrome cases